US · Healthcare · Biotechnology
EPS came in at -0.95 against a street estimate of -0.74 — a miss of 28.4%.
with an average price target of $69.44.
| Fund | Stake |
|---|---|
| EcoR1 Capital, LLC | 8.88% |
| TCG Crossover Management, LLC | 8.10% |
| Affinity Asset Advisors, LLC | 5.69% |
| Trails Edge Capital Partners, LP | 4.24% |
| Sanofi | 2.30% |
| Adage Capital Partners Gp LLC | 2.04% |
| Palo Alto Investors, LLC | 1.69% |
| Federated Hermes Inc | 0.81% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 FIRST TRACKS BIOTHERAPEUTICS, INC. — 10-Q SUMMARY FOR Q2 2026 HEADLINE NUMBERS • Cash position: $168.0 million as of June 30, 2026 (down from $238.2 | 2026-08-12 |
| Results announced · Q3 2026 FIRST TRACKS BIOTHERAPEUTICS Q2 2026 SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $168.0 million as of June 30, 2026 • Net loss for six mon | 2026-08-12 |
| Material agreement · Q2 2026 FIRST TRACKS BIOTHERAPEUTICS, INC. – 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company entered into a Sublease Agreement on June 15, 2026 with Ana | 2026-06-22 |
| Quarterly report · Q1 2026 FIRST TRACKS BIOTHERAPEUTICS, INC. – 10-Q SUMMARY Q1 2026 (Three Months Ended March 31, 2026) --- HEADLINE NUMBERS • Cash and equivalents: $248.5 m | 2026-05-14 |
| Results announced · Q2 2026 FIRST TRACKS BIOTHERAPEUTICS Q1 2026 SUMMARY HEADLINE NUMBERS • Company launched April 20, 2026 as spin-off from AnaptysBio with $180 million in cas | 2026-05-14 |
| Material agreement · Q2 2026 FIRST TRACKS BIOTHERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company spun off from AnaptysBio on April 20, 2026 • Received $100.0 million in | 2026-04-20 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for First Tracks Biotherapeutics — free to start.
Google PlayApp StoreData updated 2026-09-18.